Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Penn Microbiome Therapy (University of Pennsylvania)
- Development stage
- Unknown
- Lead developer
- University of Pennsylvania
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
Penn Microbiome Therapy (PMT) refers to a suite of investigational fecal microbiota transplantation (FMT) products developed by the University of Pennsylvania for the treatment of severe or fulminant Clostridioides difficile infection (CDI). The PMT product line includes PMT-001 (enema), PMT-002 (suspension), and PMT-003 (oral capsules), all of which are manufactured from screened human donor stool using standardized protocols. The therapy is designed to restore a healthy and diverse gut microbiome, which is typically depleted in patients with recurrent or severe CDI. By reintroducing a complex community of beneficial bacteria, PMT aims to provide competitive inhibition against C. difficile and restore the intestinal environment's natural resistance to pathogen overgrowth. In clinical settings, PMT is evaluated as an adjunctive treatment administered alongside standard-of-care antibiotics to prevent recurrence and improve clinical outcomes in high-risk patients.
- Other names
- Penn Microbiome Therapy productsFecal Microbiota Transplantation productsPenn FMT
Beyond the preview
Go deeper on Penn Microbiome Therapy (University of Pennsylvania).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Penn Microbiome Therapy (University of Pennsylvania).